Payment overview · 2025
General Payments
$518.61
5 reported records · 5 companies
Healthcare provider profile · identity verified
Brian Keith Crownover, MD, FAAFP
Allopathic & Osteopathic Physicians|Family Medicine · MERIDIAN, ID · NPI 1295729085
Verified facts
What the public records show
CMS Open Payments records show Brian Keith Crownover, MD, FAAFP received $518.61 in general payments during 2025 across 5 reported records.
Medtronic, Inc. accounted for 31.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Trulicity by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$165.07 | 31.8% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $150.00 | 28.9% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $131.17 | 25.3% | 1 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $53.36 | 10.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.01 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $368.61 | 4 |
| Consulting Fee | $150.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| SIGNIA Normalized: signia |
Device | Medtronic, Inc. | $165.07 | 1 | 2025 |
Source payment records
|
|||||
| XYREM Normalized: xyrem |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $131.17 | 1 | 2025 |
Source payment records
|
|||||
| BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION Normalized: blueprint patient specific instrumentation |
Device | Stryker Corporation | $53.36 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.01 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.01 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 115 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
66 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
67 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
115 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
40 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 487 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 402 | 91 |
| Amlodipine Besylate | Amlodipine Besylate | 339 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 274 | 60 |
| Metformin Hcl | Metformin Hcl | 273 | 61 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 64 |
| Omeprazole | Omeprazole | 229 | 61 |
| Tamsulosin Hcl | Tamsulosin Hcl | 211 | 56 |
| Bupropion Xl | Bupropion Hcl | 177 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 163 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 161 | 25 |
| Alendronate Sodium | Alendronate Sodium | 146 | 40 |
| Lisinopril | Lisinopril | 144 | 39 |
| Losartan Potassium | Losartan Potassium | 128 | 36 |
| Fluoxetine Hcl | Fluoxetine Hcl | 124 | 26 |
| Clonazepam | Clonazepam | 116 | 12 |
| Mounjaro | Tirzepatide | 115 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 109 | 26 |
| Spironolactone | Spironolactone | 105 | 34 |
| Trazodone Hcl | Trazodone Hcl | 105 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 99 | 18 |
| Gabapentin | Gabapentin | 96 | 31 |
| Sertraline Hcl | Sertraline Hcl | 94 | 18 |
| Olanzapine | Olanzapine | 88 | 15 |
| Lamotrigine | Lamotrigine | 82 | suppressed |
| Topiramate | Topiramate | 82 | 14 |
| Famotidine | Famotidine | 81 | 18 |
| Levetiracetam | Levetiracetam | 81 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 80 | 17 |
| Pregabalin | Pregabalin | 80 | 16 |
| Liothyronine Sodium | Liothyronine Sodium | 78 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 76 | 34 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 76 | 20 |
| Donepezil Hcl | Donepezil Hcl | 74 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 73 | 12 |
| Potassium Chloride | Potassium Chloride | 72 | 15 |
| Carvedilol | Carvedilol | 70 | 19 |
| Mirtazapine | Mirtazapine | 70 | 14 |
| Jardiance | Empagliflozin | 67 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 19 |
| Propranolol Hcl Er | Propranolol Hcl | 67 | 13 |
| Eliquis | Apixaban | 66 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 66 | 15 |
| Farxiga | Dapagliflozin Propanediol | 64 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 26 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 63 | 15 |
| Alprazolam | Alprazolam | 61 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 60 | 17 |
| Finasteride | Finasteride | 59 | 16 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 55 | 20 |
| Aripiprazole | Aripiprazole | 54 | suppressed |
| Memantine Hcl | Memantine Hcl | 54 | 14 |
| Irbesartan | Irbesartan | 53 | 17 |
| Lorazepam | Lorazepam | 53 | 13 |
| Doxepin Hcl | Doxepin Hcl | 52 | 11 |
| Furosemide | Furosemide | 52 | 19 |
| Meloxicam | Meloxicam | 51 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 51 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 14 |
| Minoxidil | Minoxidil | 49 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 14 |
| Montelukast Sodium | Montelukast Sodium | 47 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 46 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 46 | 14 |
| Buspirone Hcl | Buspirone Hcl | 44 | suppressed |
| Lansoprazole | Lansoprazole | 41 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 40 | 12 |
| Lithium Carbonate | Lithium Carbonate | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 12 |
| Propranolol Hcl | Propranolol Hcl | 40 | suppressed |
| Trulicity | Dulaglutide | 40 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 39 | 13 |
| Clomipramine Hcl | Clomipramine Hcl | 39 | suppressed |
| Clozapine | Clozapine | 39 | suppressed |
| Ezetimibe | Ezetimibe | 39 | 13 |
| Myrbetriq | Mirabegron | 39 | 11 |
| Vraylar | Cariprazine Hcl | 39 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 14 |
| Tramadol Hcl | Tramadol Hcl | 38 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 37 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 36 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 14 |
| Baclofen | Baclofen | 33 | suppressed |
| Fluconazole | Fluconazole | 33 | suppressed |
| Risperidone | Risperidone | 33 | suppressed |
| Allopurinol | Allopurinol | 32 | 11 |
| Carbamazepine Er | Carbamazepine | 32 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Guanfacine Hcl Er | Guanfacine Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Estradiol | Estradiol | 28 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Methotrexate | Methotrexate Sodium | 28 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 27 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 27 | suppressed |
| Ramelteon | Ramelteon | 27 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 25 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 25 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 23 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 23 | suppressed |
| Zonisamide | Zonisamide | 23 | suppressed |
| Paliperidone Er | Paliperidone | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Eszopiclone | Eszopiclone | 21 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 20 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 20 | suppressed |
| Modafinil | Modafinil | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Prednisone | Prednisone | 20 | 14 |
| Valsartan | Valsartan | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Xarelto | Rivaroxaban | 19 | suppressed |
| Xcopri | Cenobamate | 19 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | 16 |
| Simvastatin | Simvastatin | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 11 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 17 | suppressed |
| Primidone | Primidone | 17 | suppressed |
| Celecoxib | Celecoxib | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 16 | suppressed |
| Binosto | Alendronate Sodium | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | 11 |
| Armodafinil | Armodafinil | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Trulance | Plecanatide | 14 | suppressed |
| Valtoco | Diazepam | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Scopolamine | Scopolamine | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Cabergoline | Cabergoline | 12 | suppressed |
| Chlorthalidone | Chlorthalidone | 12 | suppressed |
| Constulose | Lactulose | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 12 | suppressed |
| Pimecrolimus | Pimecrolimus | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Dulera | Mometasone/Formoterol | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Qudexy Xr | Topiramate | 11 | suppressed |
| Ranolazine Er | Ranolazine | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $518.61 · 5 records | Medtronic, Inc. | BLUEPRINT PATIENT SPECIFIC INSTRUMENTATION, COBENFY, MOUNJARO, SIGNIA, XYREM, XYWAV, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error